Dr. Benhammou is a transplant hepatologiost and physician-scientist interested in understanding the transition from non-alcoholic fatty liver to hepatocellular carcinoma with the goal to identify new screening tools and chemoprevention methods using lipid modulating agents, including statins.
Benhammou JN*, Rich NE*, Cholankeril G, Zhang P, Zeng W, Rao S on behalf of TLC-ECW working group: Li W, Wu X, Feng S, Fujiwara N, Meng X, Zhu S, Zaidi S, Tayob N. DETECT: Development of Technologies for Early HCC detection. Gastroenterology (in press)
Rao S, Ohshiro K, Zaidi S, Wang Z, Shetty K, Hassan MI, Mohammad T, Latham PS, Nguyen BN, Wong L, Yu H, Jogunoori W, Vacca M, Guienigault G, Allison EA, Vital-Puig A, Alvarez M, Pajukanta P, Benhammou JN, Pisegna JR, Mirshar L. Beta spectrim (SPTBN1) deficiency protects mice from highfat diet-induced liver disease and cancer development. Sci Transl Med, 2021. PMID: 34910547.
Benhammou JN, Lin J, Aby ES, Markovic D, Raman S, Lu D, Tong MJ. Characterization of hepatocellular carcinoma growth rates in non-alcoholic fatty liver disease. Hepatoma Res, 2021. PMID: 34966854.
Benhammou JN, Moon AM, Pisegna JR, Su F, Vutien P, Moylan CA, Ioannou GN. Nonalcoholic fatty liver disease metabolic factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C. Dig Dis and Sci, 2020, PMID: 32654086.
Aby ES, Winters AC, Lin Jonathan, Bui A, Kawamoto J, Goetz MB, Bhattacharya D, Pisegna JR, May F, Patel AA, Benhammou JN. A telephone and mail outreach program successfully increases uptake of hepatocellular carcinoma. Hepatol Commun 4 (6): 825-833, 2020. PMID: 32490319 PMCID: PMC7262281